文献速递临床试验与 GCP流行病学与生物统计

篮式试验、伞式试验与平台试验的系统综述:主方案研究的全景分析

Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
PubMed 文献 · Trials · 2019-09-18

该研究通过系统文献检索对主方案(篮式、伞式和平台试验)进行全景分析,旨在提高对这一新兴概念的认识。截至2019年7月8日,共纳入83项主方案(49项篮式、18项伞式、16项平台试验),发现主方案数量过去五年快速增加,多数在美国开展、研究肿瘤领域的试验性药物。

要点

  • 共纳入83项主方案:篮式49项、伞式18项、平台16项。
  • 多数主方案在美国开展(44/83)并研究肿瘤领域试验性药物(76/83)。
  • 篮式试验多为探索性(47/49)且非随机(44/49)。

核心结论

  • 预计未来数十年主方案数量将继续快速增长,需要更多努力来提高认识和培训,以将这些创新性试验设计方法应用于肿瘤以外领域。

研究设计与样本

  • 采用系统文献检索对主方案进行全景分析,于2019年7月8日检索MEDLINE、EMBASE和CENTRAL数据库,并手工检索已发表综述和注册库。
  • 共识别83项主方案,包括49项篮式试验、18项伞式试验和16项平台试验。

主要发现

  • 主方案数量在过去五年快速增加;多数在美国开展(44/83),研究试验性药物(82/83),属于肿瘤领域(76/83)。
  • 篮式试验多数为探索性(I/II期;47/49)且非随机(44/49),超过一半仅研究单一干预(28/48);中位样本量205例(IQR:500-90=410),中位研究时长22.3个月(IQR:74.1-42.9=31.1)。
  • 伞式试验多数为探索性(16/18),但随机化更常见(8/18);中位样本量346例(IQR:565-252=313),中位研究时长60.9个月(IQR:81.3-46.9=34.4),中位干预数量为5(IQR:6-4=2)。
  • 平台试验多数为随机(15/16),III期研究更常见(7/15;1项未报告分期信息),其中4项采用无缝II/III期设计;中位样本量892例(IQR:1835-255=1580),中位研究时长58.9个月(IQR:101.3-36.9=64.4)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Master protocols, classified as basket trials, umbrella trials, and platform trials, are novel designs that investigate multiple hypotheses through concurrent sub-studies (e.g., multiple treatments or populations or that allow adding/removing arms during the trial), offering enhanced efficiency and a more ethical approach to trial evaluation. Despite the many advantages of these designs, they are infrequently used. METHODS: We conducted a landscape analysis of master protocols using a systematic literature search to determine what trials have been conducted and proposed for an overall goal of improving the literacy in this emerging concept. On July 8, 2019, English-language studies were identified from MEDLINE, EMBASE, and CENTRAL databases and hand searches of published reviews and registries. RESULTS: We identified 83 master protocols (49 basket, 18 umbrella, and 16 platform trials). The number of master protocols has increased rapidly over the last five years. Most have been conducted in the US (n = 44/83) and investigated experimental drugs (n = 82/83) in the field of oncology (n = 76/83). The majority of basket trials were exploratory (i.e., phase I/II; n = 47/49) and not randomized (n = 44/49), and more than half (n = 28/48) investigated only a single intervention. The median sample size of basket trials was 205 participants (interquartile range, Q3-Q1 [IQR]: 500-90 = 410), and the median study duration was 22.3 (IQR: 74.1-42.9 = 31.1) months. Similar to basket trials, most umbrella trials were exploratory (n = 16/18), but the use of randomization was more common (n = 8/18). The median sample size of umbrella trials was 346 participants (IQR: 565-252 = 313), and the median study duration was 60.9 (IQR: 81.3-46.9 = 34.4) months. The median number of interventions investigated in umbrella trials was 5 (IQR: 6-4 = 2). The majority of platform trials were randomized (n = 15/16), and phase III investigation (n = 7/15; one did not report information on phase) was more common in platform trials with four of them using seamless II/III design. The median sample size was 892 (IQR: 1835-255 = 1580), and the median study duration was 58.9 (IQR: 101.3-36.9 = 64.4) months. CONCLUSIONS: We anticipate that the number of master protocols will continue to increase at a rapid pace over the upcoming decades. More efforts to improve awareness and training are needed to apply these innovative trial design methods to fields outside of oncology.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019. PMID: 31533793. doi:10.1186/s13063-019-3664-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。